Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May;131(5):57007.
doi: 10.1289/EHP11606. Epub 2023 May 24.

Associations of Pregnancy Per- and Polyfluoroalkyl Substance Concentrations and Uterine Fibroid Changes across Pregnancy: NICHD Fetal Growth Studies - Singletons Cohort

Affiliations

Associations of Pregnancy Per- and Polyfluoroalkyl Substance Concentrations and Uterine Fibroid Changes across Pregnancy: NICHD Fetal Growth Studies - Singletons Cohort

Susanna D Mitro et al. Environ Health Perspect. 2023 May.

Abstract

Background: Fibroids (hormonally responsive benign tumors) often undergo volume changes in pregnancy. Because per- and polyfluoroalkyl substances (PFAS) disrupt hormonal signaling, they might affect fibroid growth. We assessed associations between PFAS and fibroid changes in pregnancy.

Methods: We analyzed seven PFAS, including perfluorohexanesulfonic acid (PFHxS), perfluorooctanesulfonic acid (PFOS), perfluorodecanoic acid (PFDA), and perfluoroundecanoic acid (PFUnDA), in plasma collected at 10-13 wk gestation from 2,621 women in the NICHD Fetal Growth Studies - Singletons cohort (2009-2013). Sonographers recorded fibroid number and volume of the three largest fibroids during up to six timed ultrasounds. Generalized linear models assessed associations of baseline log2-transformed PFAS and fibroid number, volume, and presence, and weighted quantile sum regression evaluated the PFAS mixture. Generalized linear mixed models with random intercepts assessed associations of PFAS and longitudinal fibroid number and total volume. Volume analyses were stratified by total volume at first visualization [equivalent to a fibroid <1cm (small), 1 to<3cm (medium), or 3cm (large) in diameter].

Results: Fibroid prevalence was 9.4% (n=245 women). PFAS were not associated with changes in fibroid number, but were associated with volume trajectory, depending on baseline volume. Among women with small volume, PFAS were associated with fibroid growth: Each doubling in PFHxS and PFOS concentrations was associated with 3.6% [95% confidence interval (CI): 0.2, 7.0 and 5.2% (95% CI: -0.4, 11.1)] greater weekly fibroid growth, respectively. Among women with medium volume, PFAS were associated with shrinking: Doublings in PFOS, PFDA, and PFUnDA concentrations were associated with 1.9% (95% CI: 0.4, 3.3), 1.2% (95% CI: 0.1, 2.4), and 1.6% (95% CI: 0.4, 2.8) greater weekly fibroid volume reduction, respectively.

Discussion: Certain PFAS were associated with fibroid growth among women with small fibroids and decreases among women with medium fibroids. PFAS were not associated with fibroid prevalence or number; therefore, PFAS may influence prevalent fibroids rather than initiating fibroid development. https://doi.org/10.1289/EHP11606.

Trial registration: ClinicalTrials.gov NCT00912132.

PubMed Disclaimer

Figures

Figure 1 is an error bar graph, plotting percentage difference in total fibroid volume (centimeter cubed) (95 percent confidence interval), ranging from negative 100 to 300 in increments of 100 (y-axis) across perfluorooctanesulfonic acid, perfluorooctanoic acid, perfluorononanoic acid, perfluorohexanesulfonic acid, perfluorodecanoic acid, perfluoroundecanoic acid, and N-methylperfluoro-1-octane-sulfonamidoacetic acid (x-axis).
Figure 1.
Cross-sectional associations of first trimester (10–13 wk) PFAS concentrations and total fibroid volume (n=161 for all PFAS except NMeFOSAA; n=132 for NMeFOSAA). Effect estimates and 95% CIs represent percentage difference in total fibroid volume per doubling in PFAS concentration, based on parameter estimates from multivariable linear regression models adjusted for age, race/ethnicity, BMI, and education. Plotted values are listed in Supplemental Table S5. Note: BMI, body mass index; CI, confidence interval; NMeFOSAA, N-methylperfluoro-1-octane-sulfonamidoacetic acid; PFAS, per- and polyfluoroalkyl substances; PFDA, perfluorodecanoic acid; PFHxS, perfluorohexanesulfonic acid; PFNA, perfluorononanoic acid; PFOA, perfluorooctanoic acid; PFOS, perfluorooctanesulfonic acid; PFUnDA, perfluoroundecanoic acid.
Figure 2 is an error bar graph, plotting percentage change in total fibroid volume (centimeter cubed) (95 percent confidence interval), ranging from negative 5 to 15 in increments of 5 (y-axis) across perfluorooctanesulfonic acid, perfluorooctanoic acid, perfluorononanoic acid, perfluorohexanesulfonic acid, perfluorodecanoic acid, perfluoroundecanoic acid, and N-methylperfluoro-1-octane-sulfonamidoacetic acid (x-axis) for small, medium, and large.
Figure 2.
Longitudinal associations of first trimester (10–13 wk) PFAS concentrations and change in total fibroid volume across pregnancy [n=45 (small volume), n=111 (medium volume), n=89 (large volume) for all PFAS except NMeFOSAA; n=40 (small volume), n=97 (medium volume), n=67 (large volume) for NMeFOSAA]. Effect estimates and 95% CIs are weekly percentage change in total fibroid volume per doubling in PFAS concentration, based on parameter estimates from multivariable generalized linear mixed models adjusted for age, race/ethnicity, BMI, and education. Plotted values are listed in Supplemental Table S8. Note: BMI, body mass index; COI, confidence interval; NMeFOSAA, N-methylperfluoro-1-octane-sulfonamidoacetic acid; PFAS, per- and polyfluoroalkyl substances.

References

    1. Wise LA, Laughlin-Tommaso SK. 2016. Epidemiology of uterine fibroids – from menarche to menopause. Clin Obstet Gynecol 59(1):2–24, PMID: , 10.1097/GRF.0000000000000164. - DOI - PMC - PubMed
    1. Laughlin SK, Baird DD, Savitz DA, Herring AH, Hartmann KE. 2009. Prevalence of uterine leiomyomas in the first trimester of pregnancy: an ultrasound screening study. Obstet Gynecol 113(3):630–635, PMID: , 10.1097/AOG.0b013e318197bbaf. - DOI - PMC - PubMed
    1. Pérez-Roncero GR, López-Baena MT, Ornat L, Cuerva MJ, Garcia-Casarrubios P, Chedraui P, et al. 2020. Uterine fibroid and preterm birth risk: a systematic review and meta-analysis. J Obstet Gynaecol Res 46(9):1711–1727, PMID: , 10.1111/jog.14343. - DOI - PubMed
    1. Petrakis D, Vassilopoulou L, Mamoulakis C, Psycharakis C, Anifantaki A, Sifakis S, et al. 2017. Endocrine disruptors leading to obesity and related diseases. Int J Environ Res Public Health 14(10):1282, PMID: , 10.3390/ijerph14101282. - DOI - PMC - PubMed
    1. Wang Z, Cousins IT, Scheringer M, Buck RC, Hungerbühler K. 2014. Global emission inventories for C4-C14 carboxylic acid (PFCA) homologues from 1951 to 2030, part I: production and emissions from quantifiable sources. Environ Int 70:62–75, PMID: , 10.1016/j.envint.2014.04.013. - DOI - PubMed

Publication types

Associated data

LinkOut - more resources